U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07668557) titled 'Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia' on June 19.
Brief Summary: This single-arm, open-label phase I trial evaluates the safety and tolerability of ICG415, autologous CAR-T cells targeting CD33 and CLL1, in patients with relapsed or refractory acute myeloid leukemia (AML). Subjects receive lymphodepleting chemotherapy followed by autologous CAR-T infusion. The primary goal is to assess safety and preliminary anti-leukemic efficacy in patients failing standard AML therapies.
Study Start Date: June 10
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia (AML)
...